Michael Kachmann and Zachary Tempel from Mayfield Brain & Spine (Norwood, USA) and Paul Holman from Houston Methodist Hospital (Houston, USA) have successfully completed the first commercial cases with NuVasive’s Pulse platform.
Kachmann and Tempel performed the first commercial case using Pulse in an extreme lateral interbody fusion (XLIF) procedure with minimally invasive fixation and nerve root decompression at TriHealth’s Good Samaritan Hospital in Ohio, USA, and have since leveraged Pulse in a variety of spine procedures.
Kachmann said: “We have spent years waiting for a spine technology platform like Pulse. The ability for multiple surgical applications to exist in a single platform and provide integrated feedback on our surgical approach from one screen was unlike anything I’ve ever utilised in spine surgery. It was incredible to see the improvements in accuracy and efficiency throughout the procedure compared to other available technologies.”
“Pulse easily complemented how our OR staff operated. It even enhanced how we were able to move from XLIF to posterior fixation with all the necessary tools in one platform, making seamless transitions between applications”, added Tempel. “Mayfield Brain & Spine has been a strong advocate for the Pulse platform and it will become an integral part of the world-class patient care we offer.”
Pulse is an integrated technology platform designed to increase safety, efficiency, and procedural reproducibility of spine surgery. The platform allows surgeons to easily access multiple technologies from a condensed footprint and address some of the most common surgical challenges.
Holman said of his experience with Pulse: “This technology is a game changer for spine surgery—from its condensed footprint in the operating room (OR) to its utility throughout the entire procedure—this will transform the standard of spine care for patients. Having helped with the clinical development of the platform, this leading technology will advance how I work and teach in the OR, and ultimately improve patient outcomes.”
